牛牛AI助理已提取核心訊息
On May 7, 2024, 180 Life Sciences Corp. experienced significant leadership changes, as detailed in a Form 8-K report filed with the SEC. Dr. James N. Woody resigned as CEO and from the Board of Directors, entering into a separation agreement that includes a severance package and potential future contingent payment. Dr. Jonathan Rothbard also resigned as Chief Scientific Officer, with a modest cash settlement and a subsequent consulting agreement. Dr. Lawrence Steinman stepped down as Executive Chairman but remains on the Board and was appointed to the Strategy and Alternatives Committee. Blair Jordan was appointed as Interim CEO and entered into an Executive Consulting Agreement with the company. The Board of Directors set new compensation rates for non-executive Board members and entered into indemnity agreements with its directors and officers, excluding the CFO who already had such an agreement. These leadership transitions and contractual agreements are part of the company's ongoing governance and management adjustments.
On May 7, 2024, 180 Life Sciences Corp. experienced significant leadership changes, as detailed in a Form 8-K report filed with the SEC. Dr. James N. Woody resigned as CEO and from the Board of Directors, entering into a separation agreement that includes a severance package and potential future contingent payment. Dr. Jonathan Rothbard also resigned as Chief Scientific Officer, with a modest cash settlement and a subsequent consulting agreement. Dr. Lawrence Steinman stepped down as Executive Chairman but remains on the Board and was appointed to the Strategy and Alternatives Committee. Blair Jordan was appointed as Interim CEO and entered into an Executive Consulting Agreement with the company. The Board of Directors set new compensation rates for non-executive Board members and entered into indemnity agreements with its directors and officers, excluding the CFO who already had such an agreement. These leadership transitions and contractual agreements are part of the company's ongoing governance and management adjustments.
2024年5月7日，180生命科學公司經歷了重大的領導層變動，向美國證券交易委員會提交的8-K表格報告中詳述了這一點。James N. Woody博士辭去了首席執行官和董事會的職務，簽訂了離職協議，其中包括遣散費和未來可能的或有付款。喬納森·羅斯巴德博士也辭去了首席科學官的職務，達成了適度的現金結算，隨後簽訂了諮詢協議。勞倫斯·斯坦曼博士辭去了執行主席的職務，但仍在董事會任職，並被任命爲戰略與替代委員會成員。布萊爾·喬丹被任命爲臨時首席執行官，並與該公司簽訂了執行諮詢協議。董事會爲非執行董事會成員設定了新的薪酬標準，並與其董事和高級管理人員簽訂了賠償協議，但已簽訂此類協議的首席財務官除外。這些領導層過渡和合同協議是公司正在進行的治理和管理調整的一部分。
2024年5月7日，180生命科學公司經歷了重大的領導層變動，向美國證券交易委員會提交的8-K表格報告中詳述了這一點。James N. Woody博士辭去了首席執行官和董事會的職務，簽訂了離職協議，其中包括遣散費和未來可能的或有付款。喬納森·羅斯巴德博士也辭去了首席科學官的職務，達成了適度的現金結算，隨後簽訂了諮詢協議。勞倫斯·斯坦曼博士辭去了執行主席的職務，但仍在董事會任職，並被任命爲戰略與替代委員會成員。布萊爾·喬丹被任命爲臨時首席執行官，並與該公司簽訂了執行諮詢協議。董事會爲非執行董事會成員設定了新的薪酬標準，並與其董事和高級管理人員簽訂了賠償協議，但已簽訂此類協議的首席財務官除外。這些領導層過渡和合同協議是公司正在進行的治理和管理調整的一部分。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了